Several investment firms have updated their stock ratings and price targets on shares of Sarepta Therapeutic (NASDAQ: SRPT) in the last week:

  • Sarepta Therapeutic had its price target raised by analysts at Piper Jaffray from $11.00 to $38.00. They now have an “overweight” rating on the stock. They wrote, “Top-line 48-week results from the Phase IIb study of Eteplirsen showed statistically significant increases in both Dystrophin-positive fibers and 6-Minute Walk Test. We anticipate Sarepta will submit a 48-week data package for review at the end-of-Phase II meeting and seek accelerated approval under PDUFA V, and now expect the FDA may approve Eteplirsen next year, which is 2 years ahead of prior expectations. Moreover, this data and ultimate approval validates exon skipping technology for other mutations that cause Duchenne Muscular Dystrophy (DMD) – equating to a blockbuster, multibillion dollar orphan market opportunity. We reiterate our Overweight rating and are increasing our price target to $38 from $11.”
  • Sarepta Therapeutic had its price target raised by analysts at JMP Securities from $18.00 to $50.00. They now have an “outperform” rating on the stock.
  • Sarepta Therapeutic had its price target raised by analysts at ThinkEquity from $15.00 to $40.00. They now have a “buy” rating on the stock.
  • Sarepta Therapeutic had its “buy” rating reaffirmed by analysts at Lazard Capital. They now have a $54.00 price target on the stock.
  • Sarepta Therapeutic had its price target raised by analysts at Wedbush from $26.00 to $70.00. They now have a “positive” rating on the stock.
  • Sarepta Therapeutic had its “outperform” rating reaffirmed by analysts at Wedbush.

Sarepta Therapeutic traded down 4.23% on Monday, hitting $32.85. Sarepta Therapeutic has a 52-week low of $3.00 and a 52-week high of $45.00. The company’s market cap is $743.2 million.

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of both rare and infectious diseases.